JP2009520503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009520503A5 JP2009520503A5 JP2008547621A JP2008547621A JP2009520503A5 JP 2009520503 A5 JP2009520503 A5 JP 2009520503A5 JP 2008547621 A JP2008547621 A JP 2008547621A JP 2008547621 A JP2008547621 A JP 2008547621A JP 2009520503 A5 JP2009520503 A5 JP 2009520503A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla4
- composition
- molecule
- domain
- glycosylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- 230000004988 N-glycosylation Effects 0.000 claims 9
- 230000013595 glycosylation Effects 0.000 claims 9
- 238000006206 glycosylation reaction Methods 0.000 claims 9
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 6
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims 4
- 229920001542 oligosaccharide Polymers 0.000 claims 4
- 150000002482 oligosaccharides Chemical class 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 2
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 claims 2
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 claims 2
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000013628 high molecular weight specie Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000013627 low molecular weight specie Substances 0.000 claims 1
- 238000003468 luciferase reporter gene assay Methods 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
Images
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75226705P | 2005-12-20 | 2005-12-20 | |
| US75215005P | 2005-12-20 | 2005-12-20 | |
| US60/752,150 | 2005-12-20 | ||
| US60/752,267 | 2005-12-20 | ||
| US84954306P | 2006-10-05 | 2006-10-05 | |
| US60/849,543 | 2006-10-05 | ||
| PCT/US2006/049074 WO2007076032A2 (en) | 2005-12-20 | 2006-12-19 | Compositions and methods for producing a composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009289570A Division JP5097194B2 (ja) | 2005-12-20 | 2009-12-21 | 組成物および組成物の製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009520503A JP2009520503A (ja) | 2009-05-28 |
| JP2009520503A5 true JP2009520503A5 (cg-RX-API-DMAC10.html) | 2010-02-18 |
| JP5096369B2 JP5096369B2 (ja) | 2012-12-12 |
Family
ID=38218674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547621A Active JP5096369B2 (ja) | 2005-12-20 | 2006-12-19 | 組成物および組成物の製造方法 |
| JP2009289570A Active JP5097194B2 (ja) | 2005-12-20 | 2009-12-21 | 組成物および組成物の製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009289570A Active JP5097194B2 (ja) | 2005-12-20 | 2009-12-21 | 組成物および組成物の製造方法 |
Country Status (24)
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| PT2253644E (pt) | 2005-12-20 | 2014-01-23 | Bristol Myers Squibb Co | Composições e métodos para a produção de uma composição |
| EP2423220B1 (en) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| CN101970650B (zh) | 2008-03-06 | 2017-07-25 | 哈洛齐梅公司 | 可溶性透明质酸酶的大规模生产 |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| CN105435211A (zh) | 2008-10-06 | 2016-03-30 | 三维肽胶株式会社 | 组织闭塞剂 |
| CN101995476B (zh) * | 2009-08-10 | 2013-07-03 | 中国医学科学院北京协和医院 | 临床化学检验用液体质控血清 |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| US20110136682A1 (en) | 2009-12-04 | 2011-06-09 | Momenta Pharmaceuticals, Inc. | Antennary fucosylation in glycoproteins from cho cells |
| JP2013519652A (ja) * | 2010-02-12 | 2013-05-30 | ディーエスエム アイピー アセッツ ビー．ブイ． | 単一ユニット抗体精製 |
| WO2011113019A2 (en) | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| US20120121574A1 (en) * | 2010-11-15 | 2012-05-17 | Luciano Polonelli | Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore |
| JP5847418B2 (ja) | 2011-03-30 | 2016-01-20 | 富士フイルム株式会社 | 細胞接着性タンパク質 |
| EP2707723B1 (en) * | 2011-05-12 | 2016-02-10 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
| WO2013130604A1 (en) * | 2012-02-27 | 2013-09-06 | Biogen Idec Ma Inc. | High-throughput method for sialic acid quantitation |
| WO2013162951A1 (en) * | 2012-04-22 | 2013-10-31 | Perfinity Biosciences, Inc. | Automated protein digestion, recovery and analysis |
| WO2014004780A1 (en) * | 2012-06-29 | 2014-01-03 | Bristol-Myers Squibb Company | Methods for reducing glycoprotein aggregation |
| EP2869903B1 (en) * | 2012-07-06 | 2018-11-28 | 3-D Matrix Ltd. | Fill-finish process for peptide solutions |
| WO2014018747A2 (en) | 2012-07-26 | 2014-01-30 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
| ES2708759T3 (es) | 2013-05-13 | 2019-04-11 | Momenta Pharmaceuticals Inc | Procedimientos para el tratamiento de la neurodegeneración |
| EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| DK3116896T3 (en) | 2014-03-10 | 2019-03-18 | 3 D Matrix Ltd | SELF-PREPARING PEPTIME COMPOSITIONS |
| ES3037364T3 (en) | 2014-03-10 | 2025-10-01 | 3 D Matrix Ltd | Sterilization and filtration of peptide compositions |
| WO2015164595A1 (en) | 2014-04-25 | 2015-10-29 | Bristol-Myers Squibb Company | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
| JP6948942B2 (ja) * | 2014-10-15 | 2021-10-13 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用 |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| EA201890006A1 (ru) | 2015-06-10 | 2018-05-31 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Применение экзосом для лечения болезни |
| TWI579030B (zh) * | 2015-12-15 | 2017-04-21 | Ｃｇ生物技術有限公司 | 分離細胞之容器、系統及方法 |
| WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US10613081B2 (en) * | 2016-11-27 | 2020-04-07 | Alireza Palangi | Quality control system and kit for automated ELISA devices |
| CN110945593A (zh) * | 2017-06-16 | 2020-03-31 | 通用电气健康护理生物科学股份公司 | 用于预测生物反应器中的过程的产出和对生物反应器中的过程建模的方法 |
| CN109385401A (zh) * | 2017-08-10 | 2019-02-26 | 北京泰德制药股份有限公司 | 一种表达重组蛋白的cho细胞的培养方法 |
| PL3684381T3 (pl) * | 2017-09-21 | 2023-03-13 | Codiak Biosciences, Inc. | Wytwarzanie pęcherzyków zewnątrzkomórkowych w zawiesinie pojedynczych komórek z zastosowaniem zdefiniowanych chemicznie pożywek do hodowli komórkowych |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| JP7102734B2 (ja) * | 2018-01-09 | 2022-07-20 | 東洋製罐グループホールディングス株式会社 | 細胞培養方法及び装置 |
| SI3781943T1 (sl) * | 2018-04-20 | 2022-07-29 | Janssen Biotech, Inc. | Kvalifikacija kromatografske kolone v proizvodnih postopkih za proizvodnjo sestavkov protitelesa proti IL12/IL23 |
| CA3106384A1 (en) * | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
| US11965900B2 (en) * | 2018-11-09 | 2024-04-23 | Wyatt Technology, Llc | Indicating a status of an analytical instrument on a screen of the analytical instrument |
| EP3983781B1 (en) | 2019-06-14 | 2025-05-07 | Agilent Technologies, Inc. | Methods and kits to improve the fluorescent signal of dmb-labeled sialic acids |
| EP4003365A1 (en) * | 2019-07-26 | 2022-06-01 | Lifescience AS | Sialic acid for use in the treatment of psoriasis |
| CN110554107B (zh) * | 2019-08-14 | 2022-06-10 | 上海应用技术大学 | 一种高效液相色谱-质谱联用分析食用油中甘油三酯成分的方法 |
| WO2021102437A1 (en) | 2019-11-21 | 2021-05-27 | Bristol-Myers Squibb Company | Label-free n-glycan quantification methods |
| CN111398308B (zh) * | 2020-03-27 | 2023-01-17 | 上海健康医学院 | 一种片剂、胶囊铝塑泡罩包装质量自动检测方法及系统 |
| JP7415771B2 (ja) | 2020-04-24 | 2024-01-17 | 株式会社島津製作所 | 分析支援装置、分析支援方法および分析支援プログラム |
| JP7314859B2 (ja) | 2020-04-30 | 2023-07-26 | 株式会社島津製作所 | 分析支援装置、分析支援方法および分析支援プログラム |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| JP7415783B2 (ja) * | 2020-05-12 | 2024-01-17 | 株式会社島津製作所 | 分析支援装置、分析支援方法および分析支援プログラム |
| EP4196598A2 (en) * | 2020-08-14 | 2023-06-21 | Bristol-Myers Squibb Company | Method of making protein |
| EP4196597A2 (en) * | 2020-08-14 | 2023-06-21 | Bristol-Myers Squibb Company | Manufacturing process for protein |
| CN112198302B (zh) * | 2020-10-25 | 2022-12-16 | 中铁二局第一工程有限公司 | 一种细集料含泥量快速检测方法及测量工具 |
| MX2023008527A (es) * | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| CA3113278C (en) * | 2021-03-25 | 2025-08-12 | Lumex Instruments Canada (0890278 B.C. Ltd.) | Device for electrophoretic analysis of multicomponent liquid samples |
| EP4314044A4 (en) * | 2021-03-31 | 2025-02-12 | Dr. Reddy's Laboratories Limited | CELL CULTURE METHODS FOR FUSION PROTEIN ASSEMBLY |
| CN113241192B (zh) * | 2021-05-18 | 2023-06-20 | 武汉大学中南医院 | 一种证据合成方法和计算机设备 |
| JP7600875B2 (ja) * | 2021-06-01 | 2024-12-17 | 株式会社島津製作所 | 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法 |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| CA3233419A1 (en) * | 2021-09-28 | 2023-04-06 | Kashiv Biosciences, Llc | An improved process for purification of protein |
| EP4408857A4 (en) * | 2021-09-28 | 2025-11-05 | Kashiv Biosciences Llc | IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN |
| AU2022354256A1 (en) * | 2021-09-28 | 2024-04-11 | Kashiv Biosciences, Llc | An improved process for purification of fusion protein |
| JP2025016812A (ja) * | 2021-12-16 | 2025-02-05 | レグセル株式会社 | 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物 |
| US20250040546A1 (en) * | 2021-12-16 | 2025-02-06 | Bristol-Myers Squibb Company | Detergent for viral inactivation |
| US20250059230A1 (en) * | 2021-12-17 | 2025-02-20 | Kashiv Biosciences, Llc | An improved method for separation of low molecular weight proteins |
| US20250206775A1 (en) * | 2022-03-18 | 2025-06-26 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| CN116467264B (zh) * | 2023-04-14 | 2025-11-28 | 阿里健康科技(中国)有限公司 | Rf2文件的生成方法、装置、设备和存储介质 |
| US12461955B2 (en) * | 2023-09-08 | 2025-11-04 | Salesforce, Inc. | Integration flow generation using large language models |
| CN117044627B (zh) * | 2023-10-11 | 2023-12-15 | 中国科学院昆明植物研究所 | 一种高山植物塔黄的组培快繁及离体保存方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460694A (en) | 1981-03-26 | 1984-07-17 | University Of Miami | Bovine glycoproteins and use in diagnosing infectious mononucleosis |
| US4929700A (en) | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
| AU7729194A (en) | 1993-09-15 | 1995-04-03 | Alpha Therapeutic Corporation | Alpha1-acid glycoprotein purification process and product |
| US5451660A (en) | 1993-12-13 | 1995-09-19 | Genentech, Inc. | Method for purifying polypeptides |
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| CA2191733A1 (en) | 1994-06-07 | 1995-12-21 | Daniel A. Vallera | Methods for inhibiting antigen specific t cell responses |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US6656466B1 (en) | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| AU729459B2 (en) | 1996-11-15 | 2001-02-01 | Genentech Inc. | Purification of neurotrophins |
| ES2293661T3 (es) | 1996-11-27 | 2008-03-16 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteinas a. |
| ZA98533B (en) | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US20030124614A1 (en) | 1997-08-29 | 2003-07-03 | Brighams And Womens Hospital Inc. | Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof |
| WO1999028455A1 (de) | 1997-12-03 | 1999-06-10 | Roche Diagnostics Gmbh | Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| ES2228052T3 (es) | 1998-06-01 | 2005-04-01 | Genentech, Inc. | Separacion demonomeros de anticuerpos de sus multimeros utilizando cromatografia de intercambio de iones. |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6521419B1 (en) | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| CA2368797C (en) | 1999-04-26 | 2010-08-17 | Genentech, Inc. | Cell culture process |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| EP1681299B1 (en) * | 2000-03-27 | 2009-11-11 | Genetics Institute, LLC | Methods for purifying highly anionic proteins |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| TWI314933B (en) | 2000-05-26 | 2009-09-21 | Bristol Myers Squibb Compan | Soluble ctla4 mutant molecules and uses thereof |
| MXPA02012157A (es) | 2000-06-09 | 2003-06-06 | Bristol Myers Squibb Co | Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos. |
| AU2001272978A1 (en) | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel co-stimulatory molecules |
| US7183376B2 (en) * | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| CA2630062C (en) * | 2000-07-03 | 2014-10-14 | Bristol-Myers Squibb Company | Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| US6358265B1 (en) | 2000-07-18 | 2002-03-19 | Specialized Health Products, Inc. | Single-step disposable safety lancet apparatus and methods |
| MXPA03006699A (es) | 2001-01-26 | 2004-05-31 | Univ Emory | Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias. |
| ATE390931T1 (de) | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| ATE363541T1 (de) | 2002-03-26 | 2007-06-15 | Lek Tovarna Farmacevtskih | Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen |
| ES2557741T3 (es) | 2002-03-27 | 2016-01-28 | Immunex Corporation | Procedimientos para incrementar la producción de polipéptidos |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| CA2482042A1 (en) | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| SI1501369T1 (sl) | 2002-04-26 | 2015-10-30 | Genentech, Inc. | Neafinitetno čiščenje proteinov |
| WO2004000810A1 (en) | 2002-06-19 | 2003-12-31 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | A process for the production of substituted phenyl ethers |
| CA2492267C (en) | 2002-07-15 | 2013-09-10 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
| US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
| EP1575998A4 (en) | 2002-12-23 | 2007-07-25 | Bristol Myers Squibb Co | PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION |
| TWI328614B (en) * | 2002-12-23 | 2010-08-11 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| US7118222B2 (en) * | 2003-05-12 | 2006-10-10 | Seiko Epson Corporation | Optical device and protector |
| DK1639014T3 (da) | 2003-06-13 | 2011-01-17 | Biogen Idec Inc | Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf |
| NZ545314A (en) | 2003-08-04 | 2009-03-31 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| US7427659B2 (en) * | 2003-10-24 | 2008-09-23 | Amgen Inc. | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
| EP1699821B1 (en) | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PT2253644E (pt) | 2005-12-20 | 2014-01-23 | Bristol Myers Squibb Co | Composições e métodos para a produção de uma composição |
| TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| JP2010501623A (ja) | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Ｆｃ含有タンパク質の精製法 |
| KR20090058532A (ko) | 2006-08-28 | 2009-06-09 | 아레스 트레이딩 에스.에이. | Ｆｃ융합 단백질을 정제하는 방법 |
-
2006
- 2006-12-19 PT PT101532828T patent/PT2253644E/pt unknown
- 2006-12-19 DK DK10153282.8T patent/DK2253644T3/da active
- 2006-12-19 HR HRP20130975TT patent/HRP20130975T1/hr unknown
- 2006-12-19 CN CN201610350033.8A patent/CN106589132B/zh active Active
- 2006-12-19 KR KR1020117029336A patent/KR101391457B1/ko active Active
- 2006-12-19 EA EA200801571A patent/EA017765B1/ru not_active IP Right Cessation
- 2006-12-19 ES ES10153282.8T patent/ES2439641T3/es active Active
- 2006-12-19 US US12/086,786 patent/US10508144B2/en active Active
- 2006-12-19 KR KR1020087017540A patent/KR101398713B1/ko active Active
- 2006-12-19 TW TW101148477A patent/TWI423986B/zh active
- 2006-12-19 AU AU2006330922A patent/AU2006330922B2/en active Active
- 2006-12-19 PE PE2006001650A patent/PE20080556A1/es not_active Application Discontinuation
- 2006-12-19 EP EP10153282.8A patent/EP2253644B1/en not_active Revoked
- 2006-12-19 NZ NZ597215A patent/NZ597215A/xx unknown
- 2006-12-19 CA CA2836123A patent/CA2836123C/en active Active
- 2006-12-19 SI SI200631693T patent/SI2253644T1/sl unknown
- 2006-12-19 SI SI200631696T patent/SI1969007T1/sl unknown
- 2006-12-19 DK DK06848052.4T patent/DK1969007T3/da active
- 2006-12-19 JP JP2008547621A patent/JP5096369B2/ja active Active
- 2006-12-19 BR BRPI0622251-0A patent/BRPI0622251A2/pt not_active Application Discontinuation
- 2006-12-19 PT PT68480524T patent/PT1969007E/pt unknown
- 2006-12-19 EP EP06848052.4A patent/EP1969007B1/en not_active Revoked
- 2006-12-19 TW TW095147641A patent/TWI398520B/zh active
- 2006-12-19 ES ES06848052T patent/ES2433092T3/es active Active
- 2006-12-19 CA CA2634760A patent/CA2634760C/en active Active
- 2006-12-19 WO PCT/US2006/049074 patent/WO2007076032A2/en not_active Ceased
- 2006-12-19 BR BRPI0620178-4A patent/BRPI0620178B1/pt active IP Right Grant
- 2006-12-19 PL PL06848052T patent/PL1969007T4/pl unknown
- 2006-12-19 PL PL10153282T patent/PL2253644T3/pl unknown
-
2008
- 2008-06-12 IL IL192098A patent/IL192098A/en active IP Right Grant
- 2008-06-13 NO NO20082716A patent/NO20082716L/no not_active Application Discontinuation
- 2008-06-18 ZA ZA2008/05301A patent/ZA200805301B/en unknown
- 2008-06-20 MX MX2012006495A patent/MX336807B/es unknown
-
2009
- 2009-12-21 JP JP2009289570A patent/JP5097194B2/ja active Active
-
2010
- 2010-11-08 AU AU2010241289A patent/AU2010241289B2/en active Active
-
2013
- 2013-12-10 IL IL229904A patent/IL229904A0/en unknown
-
2014
- 2014-01-14 CY CY20141100030T patent/CY1114887T1/el unknown
-
2018
- 2018-07-23 US US16/042,977 patent/US10941189B2/en active Active
- 2018-07-24 US US16/044,217 patent/US10808021B2/en active Active
-
2020
- 2020-11-25 US US17/105,358 patent/US12030923B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leist et al. | Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. | |
| JP2023145581A (ja) | インターロイキン－２３受容体のペプチド阻害剤の組成物 | |
| ES2791333T3 (es) | Anticuerpos anti-MIF para su uso en el tratamiento de enfermedades inflamatorias | |
| US9394362B2 (en) | IL-21 antibodies and methods of making or using the antibodies | |
| Davies et al. | Clinical experience of IL-6 blockade in rheumatic diseases—implications on IL-6 biology and disease pathogenesis | |
| US6399078B1 (en) | Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases | |
| JP2014519524A (ja) | 抗ｐｓｇｌ−１抗体およびその使用 | |
| US10093727B2 (en) | Pan-ELR+ CXC chemokine antibodies | |
| EP2279001B1 (en) | Inhibitors of gm-csf and il-17 for therapy | |
| RU2656162C2 (ru) | Антитела к интерлейкину 6 и их применение | |
| JP2021533204A5 (cg-RX-API-DMAC10.html) | ||
| JP6865826B2 (ja) | インターロイキン１７ａを標的とする抗体、その製造方法及び応用 | |
| TWI691512B (zh) | Ｆｃ融合高親和性ＩｇＥ受體α鏈 | |
| WO2000050088A2 (en) | Biotinylated-chemokine antibody complexes | |
| JP2018502603A (ja) | 新規組換え抗ＴＮＦ−αキメラモノクローナル抗体の製造方法及び用途 | |
| AU2015275926A1 (en) | Oral composition of anti-TNF alpha antibodies | |
| RS57291B1 (sr) | Pan-elr+cxc hemokin antitela | |
| ITMI960358A1 (it) | Citochine modificate per l'uso in terapia | |
| Chopade et al. | Determination of the mitigating effect of colon-specific bioreversible codrugs of mycophenolic acid and aminosugars in an experimental colitis model in Wistar rats | |
| Duan et al. | A synthetic MD-2 mimetic peptide attenuates lipopolysaccharide-induced inflammatory responses in vivo and in vitro | |
| Al Faruque et al. | Stepwise inhibition of T cell recruitment at post-capillary venules by orally active desulfated heparins in inflammatory arthritis | |
| ITMI20011833A1 (it) | Agenti che regolano la permeabilita' vascolare | |
| JP6578546B2 (ja) | Ｌｔ阻害４価ペプチドおよびｅｔｅｃ感染症治療薬 | |
| CN120118174A (zh) | Ccr4的胞外段重组蛋白及其用途 | |
| Ducreux et al. | The inhibitory potencies of monoclonal antibodies to the macrophage adhesion molecule sialoadhesin are greatly increased following PEGylation |